Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Blood (2022) 139 (10): 1452–1468.

https://doi.org/10.1182/blood.2021013443

Published: 2022

Includes: Supplemental data

Journal Articles

Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis

Maryam Sarraf Yazdy, Andrea C. Baines, Theresa Carioti, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru, Yvette L. Kasamon, Ashley Lane, Nicholas Richardson, Marc Theoret, Nicole J. Gormley

Blood (2021) 138 (Supplement 1): 4928.

https://doi.org/10.1182/blood-2021-150446

Published: 2021

Journal Articles

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Ephraim J. Fuchs, MD MBA, Shannon R McCurdy, MD, Scott R. Solomon, MD, Tao Wang, PhD, Michelle Kuxhausen, MS, Yvette L Kasamon, MD, MHD Monzr Al Malki, MD, Shahinaz Gadalla, MD PhD, Sophie Paczesny, MDPhD, Steven GE Marsh, BSc, PhD ARCS, Bronwen E. Shaw, PhD MRCP, FRCPath, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Effie Petersdorf, MD

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-140433

Published: 2020

Journal Articles

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)

Michelle Nadeau Nguyen, Afrouz Nayernama, PharmD, Steven Christopher Jones, PharmD, Yvette L. Kasamon, MD, Peter E. Waldron, MD

Blood (2019) 134 (Supplement_1): 2189.

https://doi.org/10.1182/blood-2019-123146

Published: 2019

Journal Articles

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Hany Elmariah, MDMS, Yvette L Kasamon, MD, Marianna Zahurak, MS, Noah Tucker, CCRC, Gary Rosner, ScD, F Javier Bolanos-Meade, MD, Ravi Varadhan, PhD, Ephraim J. Fuchs, MD MBA, Amy E. DeZern, MD, Leo Luznik, MD, Richard J. Jones, PhD, Richard F Ambinder, MD

Blood (2017) 130 (Supplement 1): 3304.

https://doi.org/10.1182/blood.V130.Suppl_1.3304.3304

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Yvette L. Kasamon, Ephraim J. Fuchs, MD, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Javier Bolaños-Meade, Richard J. Jones

Blood (2016) 128 (22): 831.

https://doi.org/10.1182/blood.V128.22.831.831

Published: 2016

Journal Articles

Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT

Yvette L. Kasamon, Ephraim J. Fuchs, Javier Bolaños-Meade, Mary S. Leffell, Marianna Zahurak, Gary L. Rosner, Jonathan D. Powell, Richard F. Ambinder, Richard J. Jones, Leo Luznik

Blood (2015) 126 (23): 2002.

https://doi.org/10.1182/blood.V126.23.2002.2002

Published: 2015

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon

Blood (2014) 124 (21): 680.

https://doi.org/10.1182/blood.V124.21.680.680

Published: 2014

Journal Articles

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Shannon R. McCurdy, Christopher G. Kanakry, Yvette L. Kasamon, MD, Javier Bolanos Meade, MD, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, MD MHS, Gary L. Rosner, Sc.D, Ephraim J. Fuchs, Richard J. Jones, Leo Luznik, MD

Blood (2014) 124 (21): 730.

https://doi.org/10.1182/blood.V124.21.730.730

Published: 2014

Journal Articles

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Yvette L. Kasamon, Javier Bolaños-Meade, Douglas Gladstone, Lode J. Swinnen, Jennifer A. Kanakry, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2013) 122 (21): 2091.

https://doi.org/10.1182/blood.V122.21.2091.2091

Published: 2013

Journal Articles

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Nilanjan Ghosh, MD, PhD, Xiaobu Ye, MD, MS, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, MD, Mark Levis, MD, PhD, Lode J. Swinnen, Douglas Gladstone, MD, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 3407.

https://doi.org/10.1182/blood.V122.21.3407.3407

Published: 2013

Journal Articles

Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy)

Yvette L. Kasamon, Gabrielle Prince, Javier Bolaños-Meade, Hua-Ling Tsai, Leo Luznik, Richard F. Ambinder, Ephraim J. Fuchs, Richard J. Jones

Blood (2013) 122 (21): 158.

https://doi.org/10.1182/blood.V122.21.158.158

Published: 2013

Journal Articles

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Jennifer A. Kanakry, Meir Shamay, Yvette L. Kasamon, Hailun Li, MS, Randy D. Gascoyne, MD, Leo I. Gordon, MD, Ariela Noy, MD, Ethel Cesarman, MD, PhD, Jeannette Y Lee, Ph.D., Sandra J. Horning, MD, Richard F. Ambinder

Blood (2013) 122 (21): 4232.

https://doi.org/10.1182/blood.V122.21.4232.4232

Published: 2013

Journal Articles

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Yvette L. Kasamon, Richard J. Jones, Christopher D. Gocke, Javier Bolaños-Meade, Lode J. Swinnen, Amanda Blackford, Douglas E. Gladstone, Ephraim J. Fuchs, Richard F. Ambinder

Blood (2012) 120 (21): 3107.

https://doi.org/10.1182/blood.V120.21.3107.3107

Published: 2012

Journal Articles

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice M. Davis-Sproul, Nilanjan Ghosh, Heather J. Symons, MD, MHS, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2012) 120 (21): 3084.

https://doi.org/10.1182/blood.V120.21.3084.3084

Published: 2012

Journal Articles

Blastic transformation of mantle cell lymphoma

Yvette L. Kasamon, Kathleen H. Burns

Blood (2012) 120 (12): 2359.

https://doi.org/10.1182/blood-2011-12-396408

Published: 2012

Journal Articles

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie L. Popplewell, Thomas M. Habermann, Joseph M. Herman, William H. Matsui, Richard J. Jones, Richard F. Ambinder

Blood (2012) 119 (18): 4129–4132.

https://doi.org/10.1182/blood-2012-01-402792

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy)

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Blastic transformation of mantle cell lymphoma

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only